Aquestive Therapeutics ( (AQST) ) just unveiled an announcement.
Aquestive Therapeutics reported its financial results for the fourth quarter and full year of 2024, highlighting the initiation of the Anaphylm NDA filing process with the FDA, with a potential launch in early 2026. The company also announced progress in its AQST-108 topical gel development for alopecia areata, aiming to start Phase 2a trials in 2025. Despite a decrease in total revenues by 10% compared to the previous year, the company is advancing its strategic priorities, including the launch of Libervant for young ARS patients, although facing legal challenges regarding its FDA approval.
More about Aquestive Therapeutics
Aquestive Therapeutics is a pharmaceutical company focused on developing innovative medicines that improve patients’ lives through advanced science and delivery technologies. Their primary products include non-device based treatments for severe allergic reactions and topical gels for alopecia areata, with a market focus on providing alternatives to existing systemic treatments.
YTD Price Performance: -25.61%
Average Trading Volume: 1,728,766
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $248.9M
For an in-depth examination of AQST stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com